6 news items
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
VERV
8 May 24
and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
VERV
7 May 24
that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV
3 May 24
to ten new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering
Verve Therapeutics Announces Updates on its PCSK9 Program
VERV
2 Apr 24
and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
VERV
1 Mar 24
awards to three new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering
c7hd7ndrg813rk0k6cw7ycqtfg5lkmyf903
VERV
27 Feb 24
on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially
- Prev
- 1
- Next